IMF TV

From our weekly series “Ask Dr. Durie” to comprehensive news from key cancer medical conferences around the world, IMF-TV is your all-access ticket to critical myeloma research, patient education and guidance. Check back often for regularly updated content. 

Dec
05
ASH 2018: Blood Monitoring
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about will blood monitoring become a reliable and practical method with Dr. Joseph Mikhael (IMF Chief Medical Officer) and(...)
Dec
05
ASH 2018: Maintenance Therapy
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about new information on maintenance therapy with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Maria Victoria(...)
Dec
05
ASH 2018: Frontline Therapy
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about will blood monitoring become a reliable and practical method with Dr. Joseph Mikhael (IMF Chief Medical Officer) and(...)
Dec
05
ASH 2018: CAR T-cell Therapies
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about CAR T therapieswith Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Maria Victoria Mateos (University of(...)
Dec
05
ASH 2018: Bispecific T-cell Engagers (BiTEs)
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about what is the future for BiTEs versus CAR T therapies with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Maria(...)
Dec
04
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Daratumumab (DARA) is a human IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action. DARA (16 mg/kg administered intravenously [IV]) is approved in many(...)